Core Insights - Beyond Oil Ltd. has successfully delivered its first shipment of proprietary oil treatment products to T&J Oil Pty Ltd. as part of a five-year distribution agreement aimed at expanding into the Australian market [1][2][3] - The initial shipment consisted of 5.4 tonnes of products and is part of a minimum purchase commitment of approximately US$4.9 million [2] - The partnership with T&J Oil is expected to transform the food service industry in Australia by providing healthier and more sustainable frying solutions [3] Company Overview - Beyond Oil Ltd. is a food-tech innovation company focused on reducing health risks associated with fried food while enhancing sustainability and lowering operational costs [1][4] - The company's patented technology has received regulatory clearances from the FDA and Health Canada, significantly reducing harmful compounds in frying oil [4] - Beyond Oil addresses the widespread practice of reusing frying oil, which poses health risks such as links to cancer and cardiovascular diseases, by offering solutions that improve food quality and reduce environmental impact [4]

Conference call at 4:30 p.m. ET today, February 10 Exhibit 99.1 Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH in Europe and Market Authorization in Australia; international shipments to commence later this year Garden City, NY, February 10, 2025 – Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial ...

Beyond Air, Inc. (NASDAQ:XAIR) Q3 2025 Results Conference Call February 10, 2025 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Executive Officer Doug Larson - Chief Financial Officer Conference Call Participants Jason Wittes - Roth Partners Sam Eiber - BTIG Jason Bednar - Piper Sandler Justin Walsh - JonesTrading Yale Jen - Laidlaw & Company Operator Good afternoon, and welcome everyone to the Beyond Air Financial Results Call for the Fisc ...

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this company would post a loss of $0.30 per share when it actually produced a loss of $0.28, delivering a surprise of 6.67%.Over the last four quarters, the company has surpasse ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ Commission File Number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) | Delaware | 47-3812456 | | --- | --- ...

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international shipments to commence later this year Conference call at 4:30 p.m. ET today, February 10th GARDEN CITY, New York, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power o ...

VANCOUVER, B.C., KIBBUTZ YIFAT, Israel, and NEW YORK, NY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (CSE: BOIL) (OTCQB: BEOLF) (Frankfurt: UH9) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste, and enhancing sustainability, is pleased to announce that it has successfully delivered the first order under its previously announced Master Distribution Agreement with Latitude Ltd ...

GARDEN CITY, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced it received a notification from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has been granted an additional 180-day compliance period, or until August 4, 2025 to regain compliance with Nasdaq’s minimum bid pr ...

Core Insights - Beyond Air, Inc. plans to report its financial results for the fiscal third quarter 2025, which ended on December 31, 2024, on February 10, 2025, after market close [1] - The company will host a conference call and webcast on February 10, 2025, at 4:30 PM ET to discuss the financial results [2] Company Overview - Beyond Air is a commercial stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to enhance the lives of patients with respiratory illnesses, neurological disorders, and solid tumors [3] - The company has received FDA approval for its LungFit® PH system, aimed at treating term and near-term neonates with hypoxic respiratory failure [3] - Beyond Air is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [3] - The company has partnered with The Hebrew University of Jerusalem to develop a pre-clinical program for treating autism spectrum disorder and other neurological disorders [3] - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring ultra-high concentrations of NO for targeting specific solid tumors in pre-clinical settings [3]

GARDEN CITY, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the LungFit® PH has received market authorization from the Australian Therapeutic Goods Administration (TGA) for sale as a Class IIb medical device to deliver nitric oxide, a vasodilator, generated by the device into the i ...